AUPH has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
AUPH has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Aurinia Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $359.5 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.
Total Stockholders Equity is used to calculate Book Value per Share. Aurinia Pharmaceuticals's Book Value per Share for the quarter that ended in Mar. 2024 was $2.50. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Aurinia Pharmaceuticals's Debt-to-Equity for the quarter that ended in Mar. 2024 was 0.25.
The historical data trend for Aurinia Pharmaceuticals's Total Stockholders Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aurinia Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Total Stockholders Equity | Get a 7-Day Free Trial | 298.60 | 407.75 | 479.09 | 405.44 | 377.95 |
Aurinia Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Total Stockholders Equity | Get a 7-Day Free Trial | 390.41 | 392.29 | 391.88 | 377.95 | 359.48 |
Aurinia Pharmaceuticals (NAS:AUPH) Total Stockholders Equity Explanation
1. Total Stockholders Equity is used to calculate Book Value per Share.
Aurinia Pharmaceuticals's Book Value per Share for the quarter that ended in Mar. 2024 is
Book Value per Share | = | (Total Stockholders Equity | - | Preferred Stock) | / | Shares Outstanding (EOP) |
= | (359.476 | - | 0) | / | 143.69 | |
= | 2.50 |
2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.
Aurinia Pharmaceuticals's Debt-to-Equity for the quarter that ended in Mar. 2024 is
Debt-to-Equity | = | Total Debt | / | Total Stockholders Equity | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | Total Stockholders Equity | |
= | (14.723 | + | 73.814) | / | 359.476 | |
= | 0.25 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Aurinia Pharmaceuticals's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.
Robert T Foster | director | C/O CONTRAVIR PHARMACEUTICALS, INC., 399 THORNALL STREET, FIRST FLOOR, EDISON NJ 08837 |
Karen L. Smith | director | C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2 |
Jeffrey Allen Bailey | director | BIODELIVERY SCIENCES INTERNATIONAL, INC., 4131 PARKLAKE AVE., SUITE 225, RALEIGH NC 27612 |
R. Hector Mackay-dunn | director | #1203-4464 MARKHAM STREET, VICTORIA A1 V8Z7X8 |
Jayne David R.w. | director | #1203-4464 MARKHAM STREET, VICTORIA A1 BC V8Z7X8 |
Jill Leversage | director | #1203-4464 MARKHAM STREET, VICTORIA A1 V8Z 7X8 |
Daniel Billen | director | #1203-4464 MARKHAM STREET, VICTORIA A1 V8Z 7X8 |
Joseph P Hagan | director | 3344 N. TORREY PINES COURT, SUITE 200, LA JOLLA CA 92037 |
Brinda Balakrishnan | director | #1203-4464 MARKHAM STREET, VICTORIA A1 V8Z7X8 |
Peter Greenleaf | director, officer: Chief Executive Officer | ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878 |
Joseph M Miller | officer: Chief Financial Officer | C/O CERECOR INC., 400 EAST PRATT STREET, SUITE 606, BALTIMORE MD 21202 |
Stephen P. Robertson | officer: EVP, General Counsel | #1203-4464 MARKHAM STREET, VICTORIA A1 BC V8Z7X8 |
Milne George M Jr | director | |
Matthew Maxwell Donley | officer: Ex VP, Intern'l Operations | 4520 EAST WEST HIGHWAY, 3RD FLOOR, BETHESDA MD 20814 |
Scott Michael Habig | officer: Chief Commercial Officer | #1203-4464 MARKHAM STREET, VICTORIA A1 V8Z7X8 |
From GuruFocus
By Business Wire • 10-19-2023
By Business Wire Business Wire • 06-01-2023
By Business Wire • 11-02-2023
By Business Wire • 09-21-2023
By Business Wire Business Wire • 05-26-2023
By Business Wire • 06-29-2023
By Business Wire Business Wire • 01-25-2023
By Business Wire • 07-19-2023
By Business Wire Business Wire • 05-02-2023
By Business Wire Business Wire • 02-07-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.